Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q2 FY26 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Nov 6, 2025
Slide 1: Exchange filing cover letter
November 6, 2025 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dear Sir, Please
Slide 2: Earnings Presentation: Q2 & H1 FY26
Zydus Lifesciences Limited Earnings Presentation: Q2 & H1 FY26 6th November, 2025 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Q2 FY26: At a Glance
Q2 FY26: At a Glance Revenues from Highlights of Q2 FY26 R&D Operations ❑ Total revenues registered robust growth of 17% YoY. Rs. 61,232 mn Rs. 4,820 mn ❑ India branded formulations sustained the growth momentum and 17% YoY 7.9% of revenues outpaced the market growth for yet another quarter. ❑ Consu
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 71.9% 69.9 % 74.0 % 72.8 % 72.4% 65,279 65,737 61,232 48,308 47,842 52,370 52,691 44,327 37,656 36,857 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Total R&D (Rs. mn) and %
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 14,668 4,911 13,905 12,928 4,020 10,235 3,202 9,112 3,017 2,907 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Net Debt to EBITDA (x) Net Working Capital* (Rs. mn) 72,513 0.30 62,596 60,5
Slide 7: India Formulations business
India Formulations business Sustained market outperformance driven by chronic portfolio Highlights for the quarter India Formulations Sales (Rs. mn) Q2 FY26 Revenue ▪ Branded formulations business outpaced IPM growth 15,394 15,931 Contribution for yet another quarter with 9% YoY growth led by 14,703
Slide 8: Consumer Wellness
Consumer Wellness Expanding international presence through CCL acquisition Dominant market share across key brands Consumer Wellness Sales (Rs. mn) Q2 FY26 Revenue Contribution 9,081 8,549 Brand Name Mkt Share % Mkt Rank 6,374 32.9%* 1* 4,875 4,488 Facial Cleansing # 7.9%* 5* Scrub 48.5%* 1* Q2 FY25
Slide 9: US Formulations business
US Formulations business Sustained growth through execution excellence Highlights for the quarter US Formulations Sales (Rs. mn) Q2 FY26 Revenue Contribution 31,817 ▪ Launched 7 new products. 31,307 27,437 24,168 24,096 ▪ Filed 6 ANDAs and received approval for 4 ANDAs (incl. 1 tentative approval).
Slide 10: International Markets Formulations business
International Markets Formulations business Strong growth driven by robust execution across markets Highlights for the quarter IM Formulations Sales (Rs. mn) Q2 FY26 Revenue Contribution 7,265 7,513 ▪ Growth was broad based across key geographies driven by strong demand and focused execution. 5,389
Slide 11: Updates on Innovation
Updates on Innovation NCE: Saroglitazar Magnesium • Reported positive topline results from the pivotal EPICSTM-III Phase 2(b)/3 clinical trial of Saroglitazar Magnesium in patients with PBC for the US market. • The trial met the primary endpoint, with a statistically significant treatment difference
Slide 12: Zydus at a Glance
Zydus at a Glance ~$2.75 4th 10 R&D Centers Largest generic Co. in US For NCE, APIs, Generics, Vaccines bn Global Revenues1 in terms of prescription3 Biosimilars, Wellness and Med-tech products Among 1st Revenues from Branded Approved product for >45% In >60% of product Business (Formulations and To
Slide 13: ESG Updates
ESG Updates Zydus Lifesciences Limited won the CII - Best 2023 2024 2025 Environment Project 2025 for its project “Life Cycle Assessment of Mesalamine” 55 59 61 2023 2024 2025 29.5- Medium 29.5- Medium 28.6- Medium Risk Risk Risk Zydus Lifesciences Limited commitment to become Net Zero by 2050 accep
Slide 14: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q2 Q2 YoY Q1 QoQ YoY Rs. mn H1 FY26 H1 FY25 FY26 FY25 gr. FY26 gr. gr. Total Income from Ops. 61,232 52,370 16.9% 65,737 -6.9% 1,26,969 1,14,445 10.9% Gross Contribution (GC) 44,327 37,656 17.7% 47,842 -7.3% 92,169 83,870 9.9% Gross Margin % 72.4% 71.9%
Slide 15: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q2 Q2 YoY H1 H1 YoY Rs. mn FY26 FY25 gr. % FY26 FY25 gr. % A. On operating transactions (above EBITDA line) -3,776 -423 -792.7% -4,275 -191 -2138.2% a. Included in COGS 365 31 1077% 437 11 3872.7% c. Part of other operating expenses (shown separately) -4,141 -45
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C